Human Immunodeficiency Virus Infections Clinical Trial
Official title:
A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir (LPV/r) Tablets 800/200 Milligram (mg) Once-Daily (QD) Versus 400/100 mg Twice-Daily (BID) When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-Experienced, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects
The purpose of this study was to compare the safety, tolerability, and antiviral activity of once-daily (QD) and twice-daily (BID) dosing of the lopinavir/ritonavir (LPV/r) tablet formulation in combination with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in antiretroviral-experienced human immunodeficiency virus type 1 infected subjects with detectable viral load while receiving their current antiretroviral therapy.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03563742 -
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
|
Phase 3 | |
| Completed |
NCT00294918 -
An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT00888446 -
Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid
|
Phase 2 | |
| Completed |
NCT00262522 -
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects
|
Phase 3 | |
| Completed |
NCT00294164 -
Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT00332306 -
Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment
|
Phase 3 | |
| Completed |
NCT00727597 -
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
|
Phase 3 | |
| Completed |
NCT02452242 -
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
|
Phase 2 | |
| Active, not recruiting |
NCT00376012 -
Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis
|
Phase 3 | |
| Completed |
NCT00749840 -
Attitudes and Beliefs and the Steps of HIV Care
|
N/A |